| Literature DB >> 28257502 |
Alexander Hammer1, Anahi Steiner1, Ghassan Kerry1, Gholamreza Ranaie1, Ingrid Baer2, Christian M Hammer3, Stefan Kunze4, Hans-Herbert Steiner1.
Abstract
OBJECTIVE: This prospective study is designed to detect changes in the treatment of ruptured intracranial aneurysms over a period of 17 years.Entities:
Mesh:
Year: 2017 PMID: 28257502 PMCID: PMC5336199 DOI: 10.1371/journal.pone.0172837
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Exclusion criteria for endovascular treatment.
Fisher-exact tests and chi-square tests examine the 0-Hypothesis H0 that there is no difference regarding the exclusion criteria of endovascular treatment between the two chronological groups (1997 to 2003 versus 2006 to 2009 and 2012 to 2014). Special configurations of the aneurysms and clinical factors affected the specialists’ decision of the choice of treatment and have been documented as "no specified reasons."
| Exclusion criteria | 1997–2003 | 2006–2009 and 2012–2014 | p |
|---|---|---|---|
| Dome–neck ratio <1.5 | 52 (21.1%) | 14 (9.7%) | 0.0037 |
| Neck width | 55 (22.4%) | 9 (6.3%) | < 0.0001 |
| Endovascular approach not feasable | 33 (13.4%) | 7 (4.9%) | 0.0087 |
| Far distal aneurysm | 35 (14.2%) | 55 (38.2%) | < 0.0001 |
| Intracranial haematoma | 22 (8.9%) | 29 (20.1%) | 0.0015 |
| Aneurysm causing mass effect | 3 (1.2%) | 2 (1.4%) | 1.0 |
| Patient refused | 1 (0.4%) | 1 (0.7%) | 1.0 |
| No specified reasons | 38 (15.4%) | 21 (14.6%) | 0.82 |
| Coil placement failed or occlusion incomplete | 7 (2.8%) | 6 (4.2%) | 0.56 |
| Overall | 246 (100%) | 144 (100%) | n/a |
Characteristics of the included early patient collective (1997 to 2003).
ACA: Anterior communicating artery, Anterior cerebral artery; ICA: Internal carotid artery; MCA: Middle cerebral artery; VA: Vertebral artery; BA: Basilar artery. Fisher-exact tests and Chi-Square tests examine the 0-Hypothesis H0 that there is no difference between the intervention modalities (endovascular group versus microsurgical group) regarding the ratios of the specific patient characteristics (e. g. ratio “WFNS°I-II” to “not WFNS°I-II” in the endovascular group versus ratio “WFNS°I-II” to “not WFNS°I-II” in the microsurgical group).
| 1997–2003 | Endovascular | Microsurgical | OR | 95% CI | p |
|---|---|---|---|---|---|
| Overall n = 361 | 115 | 246 | |||
| WFNS Grade | |||||
| WFNS I-II | 48 (41.7%) | 137 (55.7%) | 0.57 | 0.36–0.89 | 0.013 |
| WFNS III | 38 (33.0%) | 50 (20.3%) | 1.93 | 1.18–3.18 | 0.0087 |
| WFNS IV-V | 29 (25.2%) | 59 (24.0%) | 1.07 | 0.64–1.78 | 0.81 |
| Sex | |||||
| m | 49 (42.6%) | 91 (37.0%) | 1.26 | 0.81–1.99 | 0.31 |
| w | 66 (57.4%) | 155 (63.0%) | 0.79 | 0.50–1.24 | 0.31 |
| Location | |||||
| ACA | 59 (51.3%) | 73 (29.7%) | 2.5 | 1.58–3.94 | < 0.0001 |
| ICA | 28 (24.3%) | 99 (40.2%) | 0.48 | 0.29–0.79 | 0.0032 |
| MCA | 2 (1.7%) | 65 (26.4%) | 0.049 | 0.012–0.21 | < 0.0001 |
| VA/BA | 26 (22.6%) | 9 (3.7%) | 7.69 | 3.47–17.06 | < 0.0001 |
Characteristics of the included recent patient data (2006 to 2009 and 2012 to 2014).
ACA: Anterior communicating artery, Anterior cerebral artery; ICA: Internal carotid artery; MCA: Middle cerebral artery; VA: Vertebral artery; BA: Basilar artery. Fisher-exact tests and Chi-Square tests examine the 0-Hypothesis H0 that there is no difference between the intervention modalities (endovascular treatment group versus microsurgical treatment group) regarding the ratios of the specific patient characteristics (e. g. ratio “WFNS°I-II” to “not WFNS°I-II” in the endovascular group versus ratio “WFNS°I-II” to “not WFNS°I-II” in the microsurgical group).
| 2006–2009 and 2012–2014 | Endovascular | Microsurgical | OR | 95% CI | p |
|---|---|---|---|---|---|
| Overall n = 281 | 137 | 144 | |||
| WFNS Grade | |||||
| WFNS I-II | 69 (50.4%) | 73 (50.7%) | 0.99 | 0.62–1.58 | 1.00 |
| WFNS III | 17 (12.4%) | 24 (16.7%) | 0.71 | 0.36–1.39 | 0.31 |
| WFNS IV-V | 51 (37.2%) | 47 (32.6%) | 1.22 | 0.75–2.00 | 0.42 |
| Sex | |||||
| m | 58 (42.3%) | 49 (34.0%) | 1.42 | 0.88–2.31 | 0.15 |
| w | 79 (57.7%) | 95 (66.0%) | 0.70 | 0.43–1.14 | 0.15 |
| Location | |||||
| ACA | 69 (50.4%) | 36 (25.0%) | 3.04 | 1.84–5.04 | < 0.0001 |
| ICA | 39 (28.5%) | 20 (13.9%) | 2.47 | 1.35–4.50 | 0.0027 |
| MCA | 7 (5.1%) | 84 (58.3%) | 0.039 | 0.017–0.088 | < 0.0001 |
| VA/BA | 22 (16.1%) | 4 (2.8%) | 6.70 | 2.24–19.99 | 0.00012 |
Efficacy and safety of the treatment modalities from 1997 to 2003.
Fisher-exact tests and Chi-Square tests examine the 0-Hypothesis H0 that there is no difference regarding the rates of symptomatic ischemic stroke, occlusion rate, rebleeding, direct mortality and reinterventions between the two treatment modalities (endovascular group versus microsurgical group).
| 1997–2003 | Endovascular | Microsurgical | OR | 95% CI | p |
|---|---|---|---|---|---|
| Overall n = 361 | 115 | 246 | |||
| Initial symptomatic ischemic stroke | 18 (15.7%) | 13 (5.3%) | 3.33 | 1.57–7.05 | 0.0011 |
| Permanent symptomatic ischemic stroke (one-year follow-up) | 16 (13.9%) | 11 (4.5%) | 3.45 | 1.55–7.71 | 0.0015 |
| Initial subtotal occlusion | 22 (19.1%) | 4 (1.6%) | 14.31 | 4.80–42.65 | < 0.0001 |
| Initial incomplete occlusion | 8 (7.0%) | 0 (0.0%) | n/a | n/a | < 0.0001 |
| Complete occlussion (22.3 months) | 65 of 102 (63.7%) | 84 of 85 (98.8%) | 0.021 | 0.0028–0.16 | < 0.0001 |
| Re-bleeding (one-year follow-up) | 7 (6 early) (6.1%) | 1 (1 early) (0.4%) | 15.88 | 1.93–130.65 | 0.0017 |
| Direct mortality | 3 (2.6%) | 3 (1.2%) | 2.17 | 0.43–10.92 | 0.39 |
| Reintervention (one-year follow-up) | 16 (7 microsurgical clipping) (13.9%) | 0 (0.0%) | n/a | n/a | < 0.0001 |
Efficacy and safety of the treatment modalities from 2006 to 2009 and 2012 to 2014.
Fisher-exact tests and Chi-Square tests examine the 0-Hypothesis H0 that there is no difference regarding the rates of symptomatic ischemic stroke, occlusion rate, rebleeding, direct mortality and reinterventions between the two treatment modalities (endovascular group versus microsurgical group).
| 2006–2009 and 2012–2014 | Endovascular | Microsurgical | OR | 95% CI | p |
|---|---|---|---|---|---|
| Overall n = 281 | 137 | 144 | |||
| Initial symptomatic ischemic stroke | 27 (19.7%) | 13 (9.0%) | 2.47 | 1.22–5.02 | 0.010 |
| Permanent symptomatic ischemic stroke (one-year follow-up) | 21 (15.3%) | 11 (7.6%) | 2.19 | 1.01–4.73 | 0.043 |
| Initial subtotal occlusion | 20 (14.6%) | 3 (2.1%) | 8.03 | 2.33–27.71 | 0.00012 |
| Initial incomplete occlusion | 9 (6.6%) | 1 (0.7%) | 10.05 | 1.26–80.46 | 0.0089 |
| Complete occlussion (13.1 months) | 73 of 114 (64.0%) | 30 of 34 (88.2%) | 0.24 | 0.078–0.72 | 0.0071 |
| Re-bleeding (one-year follow-up) | 3 (3 early) (2.2%) | 0 (0.0%) | n/a | n/a | 0.11 |
| Direct mortality | 4 (2.9%) | 1 (0.7%) | 4.30 | 0.47–38.97 | 0.20 |
| Reintervention (one-year follow-up) | 7 (1 microsurgical clipping) (5.1%) | 0 (0.0%) | n/a | n/a | 0.0060 |
Comparison of the efficacy and safety of the chronological groups (1997–2003 versus 2006 to 2009 and 2012 to 2014) regarding the endovascular procedure.
Chi-Square tests examine the 0-Hypothesis H0 that there is no difference regarding the rate of endovascular cases (n = 115) in the comprehensive group of 1997–2003 (n = 361) compared to the rate of endovascular cases (n = 137) in the comprehensive recent coiling group (n = 281) (coiling 2006–2009 and 2012–2014). Moreover Fisher-exact tests and Chi-Square tests examine the 0-Hypothesis H0 that there is no difference regarding the rates of symptomatic ischemic stroke, occlusion rate, rebleeding, direct mortality and reinterventions between the two chronological groups (“Endovascular 1997–2003” versus “Endovascular 2006–2009 and 2012–2014”).
| Endovascular treatment | Endovascular 1997–2003 | Endovascular 2006–2009 and 2012–2014 | OR | 95% CI | p |
|---|---|---|---|---|---|
| Overall n = 252 | 115 of 361 (31.9%) | 137 of 281 (48.8%) | 0.49 | 0.36–0.68 | < 0.0001 |
| Initial symptomatic ischemic stroke | 18 (15.7%) | 27 (19.7%) | 0.76 | 0.39–1.46 | 0.40 |
| Permanent symptomatic ischemic stroke (one-year follow-up) | 16 (13.9%) | 21 (15.3%) | 0.89 | 0.44–1.80 | 0.75 |
| Initial subtotal occlusion | 22 (19.1%) | 20 (14.6%) | 1.38 | 0.71–2.69 | 0.34 |
| Initial incomplete occlusion | 8 (7.0%) | 9 (6.6%) | 1.06 | 0.40–2.85 | 1.00 |
| Complete occlussion | 65 of 102 (22.3 months) (63.7%) | 73 of 114 (13.1 months) (64.0%) | 0.99 | 0.57–1.72 | 1.00 |
| Re-bleeding (one-year follow-up) | 7 (6 early) (6.1%) | 3 (3 early) (2.2%) | 2.90 | 0.73–11.46 | 0.19 |
| Direct mortality | 3 (2.6%) | 4 (2.9%) | 0.89 | 0.20–4.06 | 1.00 |
| Reintervention (one-year follow-up) | 16 (7 microsurgical clipping) (13.9%) | 7 (1 microsurgical clipping) (5.1%) | 3.00 | 1.19–7.58 | 0.017 |
Comparison of the efficacy and safety of the chronological groups (1997–2003 versus 2006 to 2009 and 2012 to 2014) regarding the microsurgical procedure.
Chi-Square tests examine the 0-Hypothesis H0 that there is no difference regarding the rate of clipped cases (n = 246) in the comprehensive group of 1997–2003 (n = 361) compared to the rate of clipped cases (n = 144) in the comprehensive recent microsurgical clipping group (n = 281) (microsurgical 2006–2009 and 2012–2014). Moreover Fisher-exact tests and Chi-Square tests examine the 0-Hypothesis H0 that there is no difference regarding the rates of symptomatic ischemic stroke, occlusion rate, rebleeding, direct mortality and reinterventions between the two chronological groups (“Microsurgical 1997–2003” versus “Microsurgical 2006–2009 and 2012–2014”).
| Microsurgical clipping | Microsurgical 1997–2003 | Microsurgical 2006–2009 and 2012–2014 | OR | 95% CI | p |
|---|---|---|---|---|---|
| Overall n = 390 | 246 of 361 (68.1%) | 144 of 281 (51.2%) | 2.04 | 1.47–2.81 | < 0.0001 |
| Initial symptomatic ischemic stroke | 13 (5.3%) | 13 (9.0%) | 0.56 | 0.25–1.25 | 0.15 |
| Permanent symptomatic ischemic stroke (one-year follow-up) | 11 (4.5%) | 11 (7.6%) | 0.57 | 0.24–1.34 | 0.19 |
| Initial subtotal occlusion | 4 (1.6%) | 3 (2.1%) | 0.78 | 0.17–3.52 | 1.00 |
| Initial incomplete occlusion | 0 (0.0%) | 1 (0.7%) | n/a | n/a | 0.37 |
| Complete occlussion | 84 of 85 (22.3 months) (98.8%) | 30 of 34 (12.8 months) (88.2%) | 11.2 | 1.20–104.23 | 0.023 |
| Re-bleeding (one-year follow-up) | 1 (1 early) (0.4%) | 0 (0.0%) | n/a | n/a | 1.00 |
| Direct mortality | 3 (1.2%) | 1 (0.7%) | 1.76 | 0.18–17.13 | 1.00 |
| Reintervention (one-year follow-up) | 0 (0.0%) | 0 (0.0%) | n/a | n/a | 1.00 |
Fig 1Microscope-based indocyanine green video angiography supporting the microsurgical occlusion of a ruptured middle cerebral artery aneurysm, which has been tested but is not used as a routine intraoperative device so far.
(A): Intraoperative illustration of the middle cerebral artery aneurysm (arrows). (B): Video angiography showing the perfusion of the untreated aneurysm (arrows). (C): After clipping no perfusion of the aneurysm is detectable any more (arrows).